ArticleVascular health and risk management2026
Ventricular Mechanics and Serum Biomarkers as Predictors of Aortic Valve Replacement in Severe Aortic Stenosis.
Article in Vascular health and risk management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Severe aortic stenosis (SAS) requires timely intervention to prevent irreversible myocardial damage. This study evaluated echocardiographic strain parameters and serum biomarkers in SAS patients and explored their value for qualifying patients for aortic valve replacement (AVR). Patients and Methods: A total of 102 patients scheduled for surgical AVR were enrolled (symptomatic: n = 58; asymptomatic: n = 44). Echocardiography was used to measure left ventricular global longitudinal strain (LV GLS), peak atrial longitudinal strain (PALS), and left ventricular mass index (LVMI). Serum levels of osteoprotegerin (OPG), receptor activator of nuclear factor kappa B ligand (RANKL), and TNF-related apoptosis-inducing ligand (TRAIL) were assessed. Follow-up occurred six months postoperatively. Statistical analyses included Mann-Whitney U, Friedman ANOVA with post hoc testing, and logistic regression (p < 0.05). Results: Symptomatic patients showed lower LV GLS (-15.2% vs -16.8%, p = 0.016) and PALS (21.8% vs 27.9%, p < 0.001) before surgery. Six months post-AVR, PALS (24.7% vs 28.6%, p = 0.03) and LVMI (108.1 vs 95.5 g/m Conclusion: LV GLS, PALS, and OPG levels are useful markers of myocardial dysfunction in SAS. Their persistence after AVR indicates ongoing structural remodeling and supports their use in preoperative evaluation beyond symptom-based assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.